List of Excipients in Branded Drug STROMECTOL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merck Sharp & Dohme LLC	STROMECTOL	ivermectin	0006-0032	ANHYDROUS CITRIC ACID
Merck Sharp & Dohme LLC	STROMECTOL	ivermectin	0006-0032	BUTYLATED HYDROXYANISOLE
Merck Sharp & Dohme LLC	STROMECTOL	ivermectin	0006-0032	CELLULOSE, MICROCRYSTALLINE
Merck Sharp & Dohme LLC	STROMECTOL	ivermectin	0006-0032	MAGNESIUM STEARATE
Merck Sharp & Dohme LLC	STROMECTOL	ivermectin	0006-0032	STARCH, CORN
Department of State Health Services Pharmacy Branch	STROMECTOL	ivermectin	55695-019	ANHYDROUS CITRIC ACID
Department of State Health Services Pharmacy Branch	STROMECTOL	ivermectin	55695-019	BUTYLATED HYDROXYANISOLE

STROMECTOL Excipient Strategy and Commercial Opportunities for Ivermectin Tablets

Last updated: August 10, 2026

STROMECTOL is Merck’s oral ivermectin tablet, approved in the United States for strongyloidiasis and onchocerciasis. Its commercial opportunity is no longer based on a strong active-ingredient patent position. The value lies in low-cost manufacturing, reliable low-dose content uniformity, pediatric and geriatric usability, differentiated dosage forms, global regulatory compliance, and supply-chain execution.

The U.S. reference product contains 3 mg ivermectin and uses microcrystalline cellulose, pregelatinized starch, magnesium stearate, and butylated hydroxyanisole as inactive ingredients [1]. Ivermectin is a low-dose, poorly water-soluble compound. That combination creates formulation challenges around blend uniformity, dissolution, dose flexibility, taste, and product stability.

What excipients are used in STROMECTOL tablets?

STROMECTOL 3 mg tablets contain four listed inactive ingredients:

Excipient	Likely formulation function
Microcrystalline cellulose	Diluent, compressibility aid, tablet-strength contributor
Pregelatinized starch	Binder and disintegrant
Magnesium stearate	Lubricant
Butylated hydroxyanisole	Antioxidant
Ivermectin	Active pharmaceutical ingredient

The product is a white, round tablet marked “MSD” on one side and “32” on the other. Each tablet contains 3 mg ivermectin [1].

The excipient system is commercially conservative. It relies on common compendial materials, conventional wet or dry granulation options, and direct-compression-compatible fillers. This reduces sourcing and regulatory risk but leaves room for formulation differentiation.

How does ivermectin’s physicochemical profile affect excipient selection?

Ivermectin is a macrocyclic lactone with very low aqueous solubility. The formulation must deliver a small amount of active consistently throughout a relatively large tablet mass. The principal technical risks are content uniformity, dissolution variability, chemical stability, and poor patient acceptability.

Content uniformity and low-dose blending

At 3 mg per tablet, ivermectin represents a small fraction of the finished tablet. Segregation can occur if ivermectin particles differ materially from the excipient particles in size, density, or morphology.

A robust generic formulation should assess:

• Particle-size distribution of ivermectin.
• Geometric dilution and premix design.
• Carrier-particle size and density.
• Blend segregation during transfer and compression.
• Sampling bias during in-process testing.
• Assay and uniformity under USP dosage-unit requirements.

Microcrystalline cellulose is useful because it supports compactability at relatively low tablet forces. Pregelatinized starch can improve binding and disintegration, but excessive starch or over-lubrication may slow dissolution.

Dissolution and bioavailability

Ivermectin’s low water solubility makes dissolution a central development parameter. Excipient changes that improve tablet hardness can reduce release. Excess magnesium stearate, prolonged lubrication, hydrophobic glidants, or high compression force may produce slower dissolution.

Potential development approaches include:

• Particle-size reduction.
• Spray-dried or co-processed excipients.
• Wetting agents.
• Surfactant-containing granules.
• Solid dispersions.
• Amorphous solid-dispersion carriers.
• Lipid-based or self-emulsifying systems.
• Cyclodextrin complexes.
• Nanocrystal or nanosuspension technology.

These approaches can improve dissolution but increase manufacturing complexity, analytical burden, and regulatory exposure. A conventional tablet with a controlled particle-size API may offer a better cost-risk profile for generic entry than a novel delivery system.

Chemical stability

Butylated hydroxyanisole in the reference formulation indicates that oxidative stability is relevant to the product design [1]. A reformulated product should evaluate:

• Peroxide levels in excipients.
• Oxygen exposure during blending and filling.
• Container-closure protection.
• Light sensitivity.
• Moisture effects on excipient and API performance.
• Stability after tablet splitting or repackaging.

Low-peroxide excipient grades and high-barrier packaging may reduce reliance on antioxidant content. A change in antioxidant strategy requires comparative stability data and careful assessment of extractables, leachables, and regional excipient requirements.

What formulation opportunities exist for STROMECTOL and generic ivermectin?

The strongest commercial opportunities are dosage-form and usability improvements rather than simple substitution of one standard filler for another.

Pediatric dispersible or orally disintegrating tablets

Ivermectin treatment can involve weight-based dosing, particularly in pediatric or public-health settings. A 3 mg tablet may not provide convenient dosing for smaller children.

Potential products include:

• 1 mg, 2 mg, or 3 mg pediatric strengths.
• Dispersible tablets.
• Orally disintegrating tablets.
• Flavor-masked chewable tablets.
• Multiparticulate sachets.
• Water-dispersible tablets for field programs.

Pediatric products face a taste challenge. Ivermectin is bitter, so taste masking may require polymer coating, ion exchange, lipid barriers, flavor systems, or complexation. The formulation must release ivermectin after swallowing without compromising dissolution.

A dispersible tablet may have stronger commercial utility than an orally disintegrating tablet in low-resource settings because it can support administration with a measured volume of water. The product should minimize sedimentation, floating, residue, and dose loss in the administration vessel.

Scored tablets and dose flexibility

A scored tablet can simplify weight-based dosing and reduce the need for multiple strengths. The design must demonstrate acceptable splitability, dose uniformity, friability, and stability after tablet subdivision.

A multi-strength portfolio remains commercially attractive where national tenders or local prescribing practices favor fixed tablet sizes. The principal development question is whether each strength can maintain content uniformity without making the tablet too small for reliable manufacture.

Improved dissolution formulations

A faster-dissolving ivermectin product could support differentiated labeling if the sponsor establishes a clinically meaningful advantage. A dissolution improvement alone generally does not create a new therapeutic product unless it supports a distinct regulatory claim, such as a new dosage form, new route, pediatric use, or clinically relevant pharmacokinetic profile.

The highest-value technologies are those that improve dissolution while preserving:

• Room-temperature stability.
• Standard tablet manufacturing.
• Low-cost excipients.
• High throughput.
• Broad geographic registration.
• Simple packaging.

What excipient patents could protect an ivermectin product?

Excipient substitution alone usually provides weak exclusivity. A commercially meaningful patent position requires a specific composition, process, performance threshold, or clinical use that is not obvious over prior ivermectin formulations.

Potential patentable subject matter includes:

Patent category	Possible claim focus	Commercial strength
Solid dispersion	Ivermectin with a defined polymer and loading range	Moderate to strong if technically supported
Nanocrystal formulation	Particle-size limits and stabilizer system	Moderate
Taste masking	Coated particles or matrix system with defined release and sensory performance	Moderate
Pediatric dosage form	Dispersible or chewable composition with defined dose and dissolution	Moderate
Manufacturing process	Granulation, coating, drying, or containment parameters	Moderate if difficult to design around
Stability system	Antioxidant, low-peroxide excipient, and packaging combination	Usually limited
Fixed-dose combination	Ivermectin with a second active ingredient	Potentially strong, but clinically and regulatorily complex
Method of use	New disease, dosing regimen, or patient population	Depends on patent validity and regulatory support

A broad claim such as “ivermectin with a pharmaceutically acceptable excipient” would face substantial validity and prior-art risk. Stronger claims would define measurable technical features, such as dissolution at a specified time point, particle-size distribution, disintegration time, moisture content, or stability profile.

When does STROMECTOL lose exclusivity?

STROMECTOL’s original U.S. approval dates to 1996. The original active-ingredient and product protection associated with ivermectin has expired. FDA records identify STROMECTOL as an approved prescription product, while generic ivermectin tablets and other ivermectin products have entered the market [1,2].

The principal commercial conclusion is that STROMECTOL does not have meaningful current market exclusivity based on the original ivermectin molecule. Any remaining protection would have to arise from later patents, regulatory exclusivity, trademarks, or proprietary manufacturing arrangements.

FDA regulatory status and Orange Book position

STROMECTOL is an FDA-approved drug marketed under NDA 050742 for treatment of strongyloidiasis due to Strongyloides stercoralis and onchocerciasis due to Onchocerca volvulus [1]. The Orange Book identifies approved drug products, patents, and exclusivity information submitted or recognized under FDA procedures [2].

Ivermectin is a small-molecule drug, not a biologic. Biosimilar regulation does not apply. Generic applicants generally proceed through the abbreviated new drug application pathway, subject to the applicable reference-product, bioequivalence, labeling, and pharmaceutical-equivalence requirements.

For a current transaction or launch decision, the relevant analysis is the live Orange Book listing and any patent certifications associated with the specific reference product. Historical expiration of the original ivermectin rights does not eliminate the need to review later formulation or method-of-use patents.

Are there Paragraph IV challenges to STROMECTOL?

Generic ivermectin products have reached the market, confirming that the core STROMECTOL product is vulnerable to generic competition. Public regulatory records should be reviewed for any current Paragraph IV certification against later-listed STROMECTOL patents.

A Paragraph IV challenge would be commercially relevant only if a live patent covers the reference product, an approved use, or a formulation necessary for the proposed generic. For an old conventional tablet, the main barriers are more likely to be bioequivalence, manufacturing quality, supply reliability, and market access than molecule-level patent protection.

Potential generic launch scenarios are:

1. A conventional 3 mg tablet that closely follows the reference product.
2. A lower-cost tablet using an alternative filler and binder system.
3. A pediatric dispersible or chewable product with differentiated excipients.
4. A product optimized for public-health tenders and tropical-climate stability.
5. A specialty formulation with improved dissolution or taste masking.

Which companies compete with STROMECTOL?

Competition exists across three commercial groups:

• Merck, the STROMECTOL sponsor.
• Generic pharmaceutical companies selling ivermectin tablets.
• Manufacturers of veterinary ivermectin products, which are not substitutes for FDA-approved human STROMECTOL products.

Generic suppliers compete primarily on price, product availability, government tenders, wholesaler contracts, and regulatory registrations. The commercial market is fragmented by jurisdiction. Brand strength remains more relevant in private prescriptions and institutional procurement than in price-sensitive public-health programs.

Veterinary ivermectin products should remain operationally separate from human pharmaceutical products. Their excipient systems, manufacturing controls, labeling, dosage strengths, and regulatory status differ. Cross-market substitution creates regulatory and product-liability risk.

What manufacturing and intellectual-property barriers affect ivermectin tablets?

Manufacturing barriers are manageable but not trivial.

API supply and particle engineering

Ivermectin API quality can materially affect dissolution and content uniformity. Suppliers should be qualified for:

• Consistent polymorphic or solid-state properties.
• Controlled particle-size distribution.
• Low bioburden.
• Residual-solvent compliance.
• Impurity control.
• Batch-to-batch dissolution performance.

A sponsor that controls particle engineering may obtain a practical advantage even without a broad formulation patent.

Excipient supply security

The reference formulation uses widely available excipients. That reduces dependence on a single supplier. Commercial risk can still arise from:

• Regional compendial differences.
• Changes in excipient peroxide values.
• Supply interruptions.
• Variability in starch functionality.
• Magnesium stearate source and surface-area differences.
• Regulatory restrictions on antioxidants in specific markets.

Dual sourcing should be supported by comparability data, not only supplier qualification.

Geographic coverage

The best geographic opportunities are markets with high demand for low-cost ivermectin, strong generic substitution, or public-health procurement. A global product should account for:

• WHO and national essential-medicine requirements.
• Climatic-zone stability.
• Local language and dosing instructions.
• Registration of excipient grades.
• Serialization and anti-counterfeit rules.
• Tender-specific pack sizes.
• Pediatric dosing practices.

A heat- and humidity-stable dispersible tablet could have greater commercial value in tropical markets than a premium U.S.-style tablet with a higher manufacturing cost.

How strong is the STROMECTOL patent estate?

The original patent estate is commercially weak because ivermectin has been marketed for decades and generic products are available. The remaining defensibility of a new ivermectin product would depend on narrow, technically supported patents around formulation, delivery, process, or use.

A practical estate-strength assessment is:

Asset	Current strategic value
Original ivermectin molecule patents	Expired
Original STROMECTOL tablet protection	Expired or commercially exhausted
Trademark rights	Brand protection, not generic exclusion
New pediatric formulation patent	Potentially meaningful
Taste-masking patent	Moderate, subject to design-around risk
Solid-dispersion or nanocrystal patent	Potentially meaningful
Manufacturing process patent	Useful if process is difficult to replicate
Method-of-use patent	Depends on statutory validity and approved labeling
Regulatory exclusivity	Generally limited for an old small-molecule product

What licensing opportunities exist for ivermectin excipient technology?

Licensing opportunities are more likely to involve platform technologies than STROMECTOL-specific rights. Relevant deal targets include:

• Taste-masking platforms.
• Nanocrystal manufacturing.
• Amorphous solid-dispersion systems.
• Pediatric dispersible-tablet technologies.
• Continuous manufacturing and low-dose blending.
• Moisture-resistant packaging.
• Co-processed excipients.

A license has the strongest commercial case where it produces a clear regulatory or market advantage, such as a new pediatric dosage form, a lower-cost manufacturing process, or a clinically supported improvement in administration.

A basic substitution of microcrystalline cellulose or starch is unlikely to justify a material royalty unless it solves a documented manufacturing problem or is tied to a proprietary supply agreement.

Key Takeaways

• STROMECTOL contains ivermectin with microcrystalline cellulose, pregelatinized starch, magnesium stearate, and butylated hydroxyanisole.
• The original ivermectin exclusivity position has expired, and generic competition is established.
• Ivermectin formulation development is driven by low solubility, low-dose content uniformity, taste, and stability.
• The most credible commercial opportunities are pediatric dispersible, chewable, orally disintegrating, scored, and dissolution-enhanced products.
• Excipient patents are most defensible when tied to measurable performance, defined compositions, or difficult manufacturing processes.
• Biosimilar risk does not apply because ivermectin is a small-molecule drug.
• Current Orange Book listings, patent certifications, and litigation records must be reviewed for any later-added rights before a launch or licensing decision.
• Manufacturing execution, API particle control, excipient sourcing, and public-health procurement are likely to matter more than the expired core patent estate.

FAQs About STROMECTOL Excipient Strategy

Can a generic ivermectin tablet use different excipients from STROMECTOL?

Yes. A generic product does not need to duplicate every inactive ingredient, but it must meet pharmaceutical-equivalence, bioequivalence, quality, dissolution, stability, and labeling requirements.

Is butylated hydroxyanisole essential to an ivermectin tablet?

Not necessarily. Its inclusion in STROMECTOL indicates a role in the reference product’s stability strategy. A reformulated product could use a different antioxidant system or packaging approach if supported by stability data.

What is the best pediatric excipient strategy for ivermectin?

A dispersible tablet with taste masking is often the strongest balance between dose flexibility, ease of administration, manufacturing cost, and use in low-resource settings. The final design must protect dissolution and dose recovery after dispersion.

Can an ivermectin excipient formulation receive new patent protection?

Yes, if the formulation contains novel and non-obvious technical features. Patent strength improves when claims define a specific excipient system, process, particle property, dissolution profile, stability result, or clinical advantage.

Does veterinary ivermectin create commercial competition for STROMECTOL?

It creates market confusion and potential illicit substitution, but veterinary products are not regulatory substitutes for human STROMECTOL. Their formulations, labeling, manufacturing controls, and approved uses are distinct.

References

1. Merck & Co., Inc. (2023). STROMECTOL (ivermectin) tablets, prescribing information. U.S. Food and Drug Administration and DailyMed.

2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

3. U.S. Food and Drug Administration. (2024). Ivermectin drug products. FDA drug databases and labeling records.

4. World Health Organization. (2023). WHO model list of essential medicines. Geneva, Switzerland: World Health Organization.